<DOC>
	<DOCNO>NCT00172107</DOCNO>
	<brief_summary>A double-blind , placebo-controlled , parallel-group study ass safety efficacy 3 dos ALX1-11 ( recombinant human parathyroid hormone [ rhPTH ( 1-84 ) ] ) ( 50 , 75 100 µg ) treatment postmenopausal osteoporosis . The primary objective study compare efficacy ALX1-11 ( 50 , 75 100 µg ) placebo term increase vertebral bone mineral density , give daily subcutaneous injection 12 month postmenopausal woman osteoporosis .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy 3 Doses ALX1-11 ( 50 , 75 , 100µg ) Treatment Postmenopausal Osteoporosis</brief_title>
	<detailed_description>Human clinical experience synthetic human parathyroid hormone fragment ( rhPTH 1-34 ) animal study ALX1-11 demonstrate consistent increase bone mineral density . Furthermore , newly form bone normal structure composition . Therefore , ALX1-11 ( recombinant human parathyroid hormone [ rhPTH 1-84 ] ) potential stimulate new bone formation osteoporotic patient thereby increase trabecular bone density prevent fracture . The clinical profile ALX1-11 expect unique , since none approve therapy osteoporosis able form quantities new bone ALX1-11 potentially capable . Patients bone density `` fracture threshold '' ( osteopenia ) , well establish vertebral fracture ( osteoporosis ) , would expect benefit treatment . Animal toxicology study complete result indicate restriction clinical usage drug . Preliminary human clinical experience ALX1-11 healthy , postmenopausal female demonstrate apparent risk frank hypercalcemia* single administration 5.0 µg/kg daily administration 7 day 2.0 µg/kg/day . Based study , anticipate therapeutic range ALX1-11 50-100 µg per day ( approx . 1.0 - 1.5 µg/kg/day ) . Therefore , dose range test study include anticipate minimally effective dose , interim dose maximally tolerable dose ( 50 , 75 100 µg ) . The efficacy 3 dose ALX1-11 assess term bone mineral density biochemical marker bone turnover postmenopausal woman . The primary objective study determine dose-response relationship ALX1-11 term bone mineral density . The efficacy 3 dose ALX1-11 relative placebo determine measurement bone mineral density ( DXA ) baseline 3 , 6 12 month . Patients administer daily subcutaneous injection 0.5 mL either 50 , 75 100 µg ALX1-11 placebo every morning 12 month . Women advise use provide calcium supplement ( 500mg elemental calcium ) maintain total daily intake 1000-1500 mg/day vitamin D supplement also provide ( 400 IU/day ) . A dietary questionnaire do visit screen , 6 15 . If patient 's total serum calcium measurement , treatment phase , demonstrate frank hypercalcemia OR pre-dose calcium level 0.5 mg/dL 0.125 mmol/L upper limit normal ( 2.78 mmol/L 11.1 mg/dL ) , patient 's serum calcium level must repeat . If upon re-test patient continue demonstrate frank hypercalcemia OR basal pre-dose calcium level continue elevate upper limit normal , patient withdrawn study . *Frank Hypercalcemia : define total serum calcium level 11.1 mg/dL 2.78 mmol/L</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<criteria>Postmenopausal woman age 5075 year Visit 1 ( least 5 year post cessation menses , FSH &gt; 20 IU/L , serum estradiol &lt; 110 pmol/L ) Vertebral bone mineral density least 2.5 S.D . mean young normal . Patients must least 2 measurable contiguous vertebral body lumbar region , L1L4 . Ability self administer injection Ability willingness give inform consent Evidence 5 vertebral fracture Evidence 2 vertebral fracture region L1L4 Presence significant cardiac disease determine history , physical examination laboratory screen e.g . cardiac dysrhythmias . Presence significant hepatic , renal , pulmonary , gastrointestinal , hematological , endocrine , immunologic , neurological psychiatric disease determine history , physical examination laboratory screen . Specifically excluded disease know contribute osteoporosis : hyperparathyroidism , hyperthyroidism , glucocorticoid excess , hyper hypocalcemia , Paget 's disease , osteogenesis imperfecta , osteomalacia severe scoliosis . Evidence lumbar fusion , osteophyte excessive degenerative disease precludes reasonable DXA measurement . History presence cancer within previous 5 year except superficial basal cell squamous cell carcinoma skin . Treatment follow therapy : Any form Estrogen within previous 6 month Prior use Etidronate 2 treatment cycle ( 2weeks/cycle ) and/or use within prior 6 month Any bisphosphonate Parathyroid Hormone use within 6 month Fluoride ( &gt; 10 mg/day ) within 12 month Any form Calcitonin within previous 4 month Thyroid hormone within previous 4 month unless TSH level find remain within normal range Other therapy know influence bone metabolism* within previous 4 month Any investigational compound within previous 3 month Abnormal serum Ca++ level : patient two ( 2 ) consecutive serum calcium 2.66 mmol/L ( 10.6 mg/dl ) exclude . History positive test Hepatitis B C , urine drug screen . History alcohol drug abuse : excess alcohol define 4 combination four ( 4 ) follow per day : 120 mL wine , 360 mL beer wine cooler 30 mL whiskey . Weight 25 % ideal body weight , ( minimum 45 kg ) list Metropolitan Life Insurance Tables ( Appendix 3 ) Deemed unsuitable , opinion investigator , reason . ( *Chronic continue use medication may affect bone calcium metabolism , e.g . thiazide diuretic , oral injectable steroid , antimitotics ( methotrexate ) , heparin , anticonvulsant supplement Vitamin D excess 1,000 IU per day Vitamin A excess 10,000 IU per day )</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Post-menopausal</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Parathyroid Hormone</keyword>
	<keyword>PTH</keyword>
	<keyword>ALX1-11</keyword>
</DOC>